This study is looking at two common medications, Labetalol and NIFEdipine ER, to see which one is better at preventing hospital readmissions for women who have high blood pressure (hypertension) after giving birth. You might be able to join if you are a woman aged 19 or older, delivering at 24 weeks gestation or more, and have high blood pressure (systolic blood pressure of 140 mmHg or higher, or diastolic blood pressure of 90 mmHg or higher) on two occasions at least four hours apart. The study aims to enroll 600 participants and will compare the risk of needing to be readmitted to the hospital within six months after delivery.

Study design

This is a randomized study, meaning participants will be randomly assigned to receive either Labetalol or NIFEdipine ER. The study plans to include 600 participants, with 300 in each treatment group.

What's involved

You would be started on either NIFEdipine XR 30mg twice a day or Labetalol 200mg three times a day. Your primary provider will adjust your medication as needed, and you will be monitored for side effects.

Compensation

Not stated in the trial record.

Follow-up

The study will track whether you are readmitted to the hospital for up to six months after delivery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.